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Introduction {#acn350901-sec-0001}
============

Myasthenia gravis (MG) is a debilitating and potentially fatal autoimmune disease characterized by autoantibodies directed against epitopes of the postsynaptic muscle membrane, including the nicotinic acetylcholine receptor (AChR) and the muscle‐specific tyrosine kinase receptor (MuSK), and complement‐mediated destruction of the postjunctional membrane. Clinical manifestations include fluctuating weakness of ocular, bulbar, respiratory, and limb muscles.[1](#acn350901-bib-0001){ref-type="ref"} Current long‐term therapies for MG include thymectomy (THX), cholinesterase inhibitors, and immunosuppressive or immunomodulatory agents. Exacerbations are typically treated with rapidly efficacious therapies such as intravenous or subcutaneous immunoglobulins (IVIg or SCIg) and therapeutic plasma exchange (TPE).

Formal recommendations for clinical research standards identified a need for validated, disease‐specific measures to assess therapeutic responses in MG clinical trials, including patient‐reported functional and quality of life quality of life measures.[2](#acn350901-bib-0002){ref-type="ref"} These recommendations led to validation studies of the Quantitative MG score (QMG),[3](#acn350901-bib-0003){ref-type="ref"} MG‐Activities of daily living profile (MG‐ADL),[4](#acn350901-bib-0004){ref-type="ref"} manual muscle test (MG‐MMT),[5](#acn350901-bib-0005){ref-type="ref"} MG‐Composite (MG‐C),[6](#acn350901-bib-0006){ref-type="ref"} and Quality of Life 15 (MG‐QoL15).[7](#acn350901-bib-0007){ref-type="ref"} These measures provide a consistent methodology for assessing clinical response and include patient‐centered outcomes. These outcome measures, particularly the QMG and MG‐ADL, are being used as primary endpoints in clinical trials for new MG therapies including: eculizumab (NCT00727194 and NCT01997229), ARGX113 (NCT03669588), RA101495 (NCT03315130), CFZ533 (NCT02565576), M281 (NCT03772587), and UCB7665 (NCT03052751). However, data on the performance of these outcome measures in the setting of rapidly efficacious therapies, such as TPE, are sparse. Published data have relied upon clinical muscle strength testing[8](#acn350901-bib-0008){ref-type="ref"} and demonstration of reduction in immunoglobulin or autoantibody levels[9](#acn350901-bib-0009){ref-type="ref"}, [10](#acn350901-bib-0010){ref-type="ref"} during and immediately following TPE, but have not utilized validated, MG‐specific outcome measures.[11](#acn350901-bib-0011){ref-type="ref"}, [12](#acn350901-bib-0012){ref-type="ref"} Data regarding the responsiveness of MG‐specific outcome measures could be invaluable in planning clinical trials of rapidly efficacious therapies for MG.

Methods {#acn350901-sec-0002}
=======

This report utilized data from an open‐label study of MG patients who received TPE for a MG exacerbation at Duke University Medical Center and The University of North Carolina at Chapel Hill Hospital. The primary objective of the trial was to characterize the immunoglobulin and autoantibody response following TPE for treatment of MG exacerbation.[13](#acn350901-bib-0013){ref-type="ref"} Secondary objectives were to evaluate changes in MG‐specific clinical outcome measures and correlate with changes in immunoglobulin and autoantibody levels. Details of the study have been reported previously.[13](#acn350901-bib-0013){ref-type="ref"} In summary, eligible subjects were ≥18 years old with detectable antibodies to the AChR (AChR+), had a clinical diagnosis of MG, and an indication for use of TPE. Major exclusion criteria included antibodies to MuSK or low‐density lipoprotein receptor‐related protein 4, and history of thymoma, thymectomy, or rituximab infusion in the 6 months prior to enrollment. Enrolled subjects received five to six TPE sessions (1 plasma volume per session) at a frequency of every other day, performed in accordance with institutional practices. Clinical assessments included the MG‐ADL, MG‐QoL15, MG‐MMT, and MGC. Immunoglobulin and autoantibody levels were performed prior to the first and third TPE sessions, after the last TPE session, and at weeks 1, 2, 3, 6, and 12 post‐TPE. Immunologic assays were performed as previously described.[13](#acn350901-bib-0013){ref-type="ref"} The primary outcome for this analysis was the change in clinical outcome scores from baseline to 2 weeks post‐TPE as this time point has been used in prior studies of TPE.[12](#acn350901-bib-0012){ref-type="ref"} Statistical significance was determined by ANOVA with one‐way repeat measures for the primary endpoints at 2 weeks post‐TPE. A clinically significant change for the purposes of this analysis was defined as a change in score of ≥3 points for the MG‐ADL, MG‐QoL, MG‐MMT, and MGC and reductions in the total score indicated clinical improvement. Linear regression analysis was used to estimate the strength of correlations between immunologic markers and clinical outcome measures. Spearman correlation was performed to calculate strength of the relationship between clinical outcome measures. All data analysis was performed using SAS® version 9.1 (SAS Institute, Cary, NC). Level of statistical significance was set at *P* \< 0.05.

Results {#acn350901-sec-0003}
=======

Demographics {#acn350901-sec-0004}
------------

Ten AChR + MG patients were enrolled. All 10 patients completed the study protocol to the primary endpoint, and one patient discontinued during the observation period after the primary outcome time point due to an unrelated stroke. Most patients were taking concomitant immunomodulatory therapy and had moderate disease severity at the time of enrollment (Table [1](#acn350901-tbl-0001){ref-type="table"}). The racial distribution and severity of disease reflect enrollment in recent MG clinical trials where patients tend to be Caucasian and MGFA Severity Class II‐IV, whereas our population was somewhat older, had a relatively short disease duration overall, and was predominantly male.

###### 

Baseline demographics of enrolled MG patients (*N* = 10).

  --------------------------------------------------------------- -------------------
  Median age in years, (range)                                    72.9 (20--86)
  Male *N* (%)                                                    6 (60%)
  Caucasian *N* (%)                                               9 (90%)
  Median BMI (kg/m^2^), range                                     28.4 (20.2--32.4)
  Concomitant MG medications                                      
  Acetylcholinesterase inhibitors                                 80%
  Corticosteroids                                                 60%
  Oral immunomodulators[1](#acn350901-note-0002){ref-type="fn"}   50%
  Median duration of MG in years, (range)                         0.8 (0.0--38.0)
  Baseline MGFA severity class                                    
  IIa                                                             20%
  IIIa                                                            30%
  IIIb                                                            40%
  Iva                                                             10%
  --------------------------------------------------------------- -------------------

Primarily mycophenolate mofetil and azathioprine.
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Clinical outcome measures {#acn350901-sec-0005}
-------------------------

The MG‐ADL, MG‐QoL15, MG‐MMT, and MG‐Composite all demonstrated a statistically significant change and a clinically significant improvement at 2 weeks post‐TPE (Table [2](#acn350901-tbl-0002){ref-type="table"} and Fig, [1](#acn350901-fig-0001){ref-type="fig"}). The maximal improvement occurred at 6 weeks (MG‐ADL, MG‐QoL) or 12 weeks (MG‐MMT and MG‐Composite) post‐TPE (Table [2](#acn350901-tbl-0002){ref-type="table"}). Individual‐level data are presented in Figures [S1--S4](#acn350901-sup-0001){ref-type="supplementary-material"}. Strong correlations were observed in the change in outcome measures at 2 weeks post‐TPE for the MG‐ADL and MG‐Composite (*r* = 0.82, *P* \< 0.003), MG‐QoL15 and MG‐Composite (*r* = 0.74, *P* \< 0.014), and MG‐MMT and MG‐Composite (*r* = 0.67, *P* \< 0.033).

###### 

Summary of clinical outcome measures (*N* = 10).

  Time point     Baseline      End of TPE      2 weeks post‐TPE   Change at 2 weeks post‐TPE   6 weeks post‐TPE   Change at 6 weeks post‐TPE                                                                               
  -------------- ------------- --------------- ------------------ ---------------------------- ------------------ ---------------------------- -------------------- ---------- ------------- ------------- --------------- --------------------
  MG‐ADL         8.7 (2.0)     8.5 (6--12)     3.9 (1.9)          3.5 (2--7)                   4.4 (2.7)          3.5 (1--9)                   −5.0 (−10 to 1)      \<0.0033   3.6 (3.5)     2.0 (0--12)   −5.3 (4.4)      --5.0 (−12 to 3)
  MG‐QoL15       28.8 (9.2)    25.0 (18--43)   20.2 (13.8)        19.5 (3--41)                 16.5 (13.7)        13.5 (2--41)                 --13.0 (−32 to 5)    \<0.001    12.8 (14.3)   5.0 (0--36)   --15.2 (11.9)   --18.0 (−32 to 10)
  MG‐MMT         29.5 (21.7)   22.5 (11--81)   15.3 (19.5)        8.0 (3--64)                  15.1 (22.0)        7.0 (2--75)                  --10 (−44 to 0)      \<0.0001   14.2 (23.2)   7.0 (1--74)   --14.3 (11.7)   −10.0 (−42 to −4)
  MG‐Composite   20.7 (4.5)    21 (12--27)     10.2 (5.2)         9.0 (4--19)                  10.0 (6.2)         8.0 (3--20)                  --10.0 (−22 to −3)   \<0.0015   10.1 (7.7)    6.0 (3--24)   --10.7 (7.3)    --14.0 (−25 to 4)

TPE, therapeutic plasma exchange; SD, standard deviation; MG, myasthenia gravis; ADL, Activities of Daily Living; QoL15, Quality of Life 15; MMT, manual muscle test.
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![Change in outcome measures relative to baseline. A negative change indicates improvement in patient‐reported (A) and clinician‐reported (B) outcome measures. Interpretation of clinical changes beyond 6 weeks post‐TPE is limited by the confounding effect of changes in concomitant medications that were permitted by the study design starting at 4 weeks post‐TPE.](ACN3-6-2114-g001){#acn350901-fig-0001}

Immunologic correlations {#acn350901-sec-0006}
------------------------

There was poor correlation between total IgG levels and MG‐Composite at baseline (*R* ^2^ = 0.018) and at 2 weeks post‐TPE (*R* ^2^ = 0.042). Correlation between AChR antibody titer and MG‐Composite score at baseline (*R* ^2^ = 0.022) and at 2 weeks post‐TPE (*R* ^2^ = 0.093) and between AChR antibody titer and MG‐ADL at baseline (*R* ^2^ \< 0.0001) and at 2 weeks post‐TPE (*R* ^2^ = 0.198) was also poor.

Discussion {#acn350901-sec-0007}
==========

Prior clinical studies of rapidly efficacious therapies such as TPE and IVIG have focused on the QMG score[10](#acn350901-bib-0010){ref-type="ref"}, [11](#acn350901-bib-0011){ref-type="ref"}, [12](#acn350901-bib-0012){ref-type="ref"}, [14](#acn350901-bib-0014){ref-type="ref"} which was the primary efficacy endpoint accepted by the U.S. Food and Drug Administration at the time. Recent trials have used the MG‐ADL as the primary or key secondary efficacy endpoint[15](#acn350901-bib-0015){ref-type="ref"} but not the MG‐QoL15. Published data from clinical trials for recently validated outcome measures, particularly the MG‐Composite, are limited and are rarely reported together. Outcome measure data from our TPE study, which included the MG‐ADL, MG‐Composite, MG‐MMT, and MG‐QoL15, will aid in the planning of future clinical trials with rapidly efficacious drugs by providing insights into sample size determination and timing of outcome measure assessment.

We found that TPE produces a rapid and statistically significant change from baseline in all outcome measures assessed 2 weeks post‐TPE. Our findings are similar to those of Barnett and colleagues[16](#acn350901-bib-0016){ref-type="ref"} who assessed MG‐QoL15 following administration of IVIG and TPE in patients with myasthenia gravis. Their evaluator‐masked trial found a mean change of −7 points in the MG‐QoL15 score at 2 weeks post‐TPE (*n* = 30), whereas our trial found a mean change of −12 points at 2 weeks post‐TPE. The observed differences in the magnitude of the MG‐QoL15 score between Barnett's study and ours may be attributable to our inclusion of a more severe disease population (70% MGFA Class III vs. 43% in Barnett), a smaller sample size (*N* = 10 vs. *N* = 30), and the unblinded nature of our study. We were not able to make any generalizations relating to age or demographics due to the small numbers, but these relationships would be worth exploring in larger studies. Our study also demonstrated that patient‐reported outcome scores continued to improve across all measures with a nadir at 6 weeks post‐TPE for the MG‐ADL and MG‐QoL15, suggesting a continued clinical effect after completion of treatment and maximal reduction of autoantibodies levels. Some of the continued reduction in patient‐reported outcomes after the completion of TPE treatment may reflect a delay in returning to a more normal lifestyle after intensive therapy and in some cases, hospitalization. This factor should be considered while planning future clinical trials that use these outcome measures as a key endpoint.

While Barnett and colleagues demonstrated correlations between the QMG score and individual items of the QoL15, our study utilized the MG‐MMT, making direct comparisons of the clinician‐reported instruments difficult. Correlation between the change in MG‐QoL15 and MG‐Composite scores was very strong, suggesting the MG‐Composite might be a reasonable benchmark for future studies to establish the yet undetermined clinically meaningful improvement in the MG‐QoL15.[17](#acn350901-bib-0017){ref-type="ref"} Data from our pilot study show a strong correlation between the MG‐ADL and MG‐Composite, which is not surprising given that the patient‐reported aspects of the MG‐Composite are derived from the MG‐ADL.

Our study[13](#acn350901-bib-0013){ref-type="ref"} demonstrated that TPE depletes immunoglobulin and AChR antibodies, but the correlation between these levels and clinical outcome measures, particularly the MG‐Composite and MG‐ADL, were not robust despite a statistically significant improvement in all outcome measures (Fig. [1](#acn350901-fig-0001){ref-type="fig"}). This finding may reflect variability in immunoglobulin and AChR antibody titers among individuals within a small overall sample size. However, our data are consistent with prior reports that similarly found that antibody titers correlate only weakly with clinical improvement.[18](#acn350901-bib-0018){ref-type="ref"}, [19](#acn350901-bib-0019){ref-type="ref"}, [20](#acn350901-bib-0020){ref-type="ref"} Such weak correlation between autoantibody and immunoglobulin titers and clinical response indicates that validated, MG‐specific clinical outcome measures should continue to be the primary means of assessing response to existing and novel rapidly efficacious therapies in clinical trials for the foreseeable future.
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**Figure S1.** Individual‐level data and Group Mean for MG -- QoL15.

**Figure S2.** Individual‐level data and Group Mean for MG -- ADL.

**Figure S3.** Individual‐level data and Group Mean for MG -- MM**T.**

**Figure S4.** Individual‐level data and Group Mean for MG -- Composite.
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